Gene · 1237
NIH grants1,226
NIH grants whose papers are about the gene, through NIH's grant-paper links.
421 to 440 of 1,226
Download this page as JSON| Grant | Title | CCR8 papers | Newest fiscal year |
|---|---|---|---|
| R01CA201312 | Targeting telomerase for melanoma therapeutics | 1 | 2020 |
| R01CA203689 | Interleukin-35 and the tumor microenvironment | 1 | 2020 |
| R01CA203721 | Transforming the diagnosis and care of patients with CTCL using TCR sequencing | 1 | 2020 |
| R01CA203834 | CD177 suppresses breast-cancer development by inhibiting beta-catenin | 1 | 2020 |
| R01CA208514 | Mechanisms of durable antitumor immunity via CD26hiCD4+ T cells | 1 | 2020 |
| R01DK015564 | Hormonal Integration of Exocrine and Endocrine Organs | 1 | 2020 |
| R01GM098943 | Molecular Mechanisms of Telomere Length Homeostasis | 1 | 2020 |
| R01HL114093 | Epigenetics of severe asthma | 1 | 2020 |
| R01HL138749 | The roles of miR-155 in regulating atherosclerosis and metabolically healthy obesity | 1 | 2020 |
| R01MD010443 | Genes, air pollution, and asthma severity in minority children | 1 | 2020 |
| R21AI139827 | Molecular mechanisms regulating leukocyte trafficking | 1 | 2020 |
| R21AI139828 | Development of a Regulatory T Cell Mimetic for Tolerance Induction in Skin Transplantation | 1 | 2020 |
| R21AI142060 | Targeting leukocyte traffic in intestinal inflammation | 1 | 2020 |
| R21AI147893 | Genetic imprints of therapeutic Ad26/MVA mosaic vaccine in rebound HIV-1 genome from acutely treated individuals | 1 | 2020 |
| R21AR072849 | Mechanisms of Macrophage Functional Switch during Skin Repair | 1 | 2020 |
| R21AR075134 | The roots of SLE: Can we cure it with a reverse transcriptase inhibitor? | 1 | 2020 |
| R21CA235139 | CCR5 inhibitors to enhance therapeutic response of breast cancer to DNA damaging agents | 1 | 2020 |
| R43AG071064 | Development of a Novel Chemokine Receptor Antagonist Peptide as a Synapse Protecting Treatment for Neurodegeneration in Alzheimer's Disease | 1 | 2020 |
| R50CA211487 | Development of Complex Natural Product Libraries and Multidimensional Anticancer Screening Platforms | 1 | 2020 |
| T32AI118697 | Pathogenesis and therapeutic targeting of immune disorders | 1 | 2020 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1237/grants?page=22